Healthy volunteers needed to test new fatty liver drug with and without food
NCT ID NCT07334080
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called ECC4703, being developed for a serious fatty liver condition (MASH). Researchers want to see how taking the drug with or without food changes the amount that gets into the blood. 72 healthy adults will receive a single dose of the drug in different forms, and their blood levels will be measured over time. This study does not treat any disease; it simply gathers information to help design future trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
CMAX Clinical Research Pty Ltd
RECRUITINGAdelaide, South Australia, 5000, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Weight-Loss surgery rewire the Liver's energy engine?
- Could a new drug tame fatty liver disease? early trial aims to find out
- Liver scan changes may foretell deadly complications
- Could a weekly shot help more people donate part of their liver?
- Experimental drug aims to reverse liver scarring in MASH cirrhosis
- Experimental drug aims to stop liver failure in MASH cirrhosis